Sprycel receives FDA approval for front line usage in newly diagnosed CML patients.

< Back to News

Bristol-Myers Squibb recently received FDA approval for the usage of Sprycel (Dasatinib) in newly diagnosed patients.  This is good news for our community as it gives yet another option in our armamentarium of drugs.

Read the press release now.